Achillion Pharmaceuticals Company Profile (NASDAQ:ACHN)

About Achillion Pharmaceuticals

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ACHN
  • CUSIP: 00448Q20
Key Metrics:
  • Previous Close: $9.22
  • 50 Day Moving Average: $8.72
  • 200 Day Moving Average: $8.19
  • Trailing P/E Ratio: 188.16
  • Foreward P/E Ratio: -46.10
  • P/E Growth: -0.84
  • Market Cap: $1.26B
  • Outstanding Shares: 136,680,000
  • Beta: 2.27
Additional Links:
Companies Related to Achillion Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $9.71 (5.36% upside)

Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateFirmActionRatingPrice TargetDetails
8/9/2016Jefferies GroupReiterated RatingHoldView Rating Details
7/14/2016Chardan CapitalInitiated CoverageSell$4.00View Rating Details
7/7/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$13.00View Rating Details
6/12/2016Leerink SwannReiterated RatingHoldView Rating Details
6/6/2016Robert W. BairdReiterated RatingOutperform$10.00View Rating Details
2/25/2016Maxim GroupReiterated RatingBuy$11.00 -> $8.00View Rating Details
12/8/2015William BlairReiterated RatingOutperform$16.00View Rating Details
5/23/2015Cowen and CompanyReiterated RatingOutperformView Rating Details
4/6/2015Deutsche Bank AGReiterated RatingBuy$25.00 -> $20.00View Rating Details
3/4/2015Barclays PLCInitiated CoverageUnderweight$8.00View Rating Details
12/12/2014Wells Fargo & Co.Reiterated RatingOutperformView Rating Details
(Data available from 8/23/2014 forward)


Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q2($0.15)($0.14)ViewN/AView Earnings Details
5/3/2016Q116($0.14)($0.13)ViewN/AView Earnings Details
2/25/2016Q4$0.09$0.12$31.40 million$31.60 millionViewN/AView Earnings Details
11/5/2015Q3$0.09$0.19$32.62 million$33.82 millionViewN/AView Earnings Details
8/10/2015Q2($0.18)($0.25)$0.71 millionViewN/AView Earnings Details
5/7/2015Q115($0.22)($0.17)ViewN/AView Earnings Details
3/5/2015Q414($0.18)($0.21)ViewN/AView Earnings Details
11/4/2014Q314($0.18)($0.16)ViewN/AView Earnings Details
8/7/2014Q214($0.18)($0.16)ViewN/AView Earnings Details
5/7/2014Q114($0.16)($0.17)ViewN/AView Earnings Details
3/7/2014Q413($0.16)($0.14)$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($0.20)($0.14)ViewN/AView Earnings Details
5/7/2013Q113($0.15)($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.17)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)
Current Year EPS Consensus Estimate: $-0.63 EPS
Next Year EPS Consensus Estimate: $-0.20 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20163($0.16)($0.16)($0.16)
Q3 20161($0.19)($0.19)($0.19)
Q4 20163($0.23)($0.17)($0.19)
(Data provided by Zacks Investment Research)


Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/30/2015David ApelianinsiderSell10,000$10.50$105,000.00View SEC Filing  
12/28/2015Mary Kay FentonCFOSell43,500$10.08$438,480.00View SEC Filing  
11/11/2015Nicole VitulloDirectorSell550,000$10.17$5,593,500.00View SEC Filing  
9/25/2015Nicole VitulloDirectorSell9,310$8.22$76,528.20View SEC Filing  
1/23/2015Mary Kay FentonCFOSell13,125$16.00$210,000.00View SEC Filing  
1/21/2015Milind DeshpandeCEOSell100,000$15.00$1,500,000.00View SEC Filing  
9/30/2014Ra Capital Management, LlcInsiderSell1,332,014$10.20$13,586,542.80View SEC Filing  
9/29/2014Ra Capital Management, LlcInsiderSell221,014$10.96$2,422,313.44View SEC Filing  
9/26/2014Ra Capital Management, LlcMajor ShareholderSell2,372,915$11.17$26,505,460.55View SEC Filing  
9/25/2014Ra Capital Management, LlcMajor ShareholderSell497,986$11.05$5,502,745.30View SEC Filing  
9/24/2014Ra Capital Management, LlcMajor ShareholderSell1,204,929$11.27$13,579,549.83View SEC Filing  
9/23/2014Ra Capital Management, LlcMajor ShareholderSell2,595,071$11.29$29,298,351.59View SEC Filing  
9/2/2014Ra Capital Management, LlcMajor ShareholderSell835,293$11.63$9,714,457.59View SEC Filing  
8/27/2014Ra Capital Management, LlcMajor ShareholderSell2,711,352$11.33$30,719,618.16View SEC Filing  
8/26/2014Ra Capital Management, LlcMajor ShareholderSell2,112,867$11.35$23,981,040.45View SEC Filing  
8/25/2014Joseph TruittEVPSell25,000$10.82$270,500.00View SEC Filing  
8/25/2014Ra Capital Management, LlcMajor ShareholderSell331,396$10.96$3,632,100.16View SEC Filing  
8/18/2014Milind DeshpandeCEOSell216,624$10.00$2,166,240.00View SEC Filing  
8/18/2014Ra Capital Management, LlcMajor ShareholderSell4,235,000$9.53$40,359,550.00View SEC Filing  
8/15/2014Michael D KishbauchDirectorSell495,812$9.40$4,660,632.80View SEC Filing  
8/13/2014Gary E FrashierDirectorSell5,000$8.00$40,000.00View SEC Filing  
6/20/2014Ra Capital Management, LlcInsiderSell880,000$8.40$7,392,000.00View SEC Filing  
6/16/2014Gary E FrashierDirectorSell55,000$8.00$440,000.00View SEC Filing  
6/16/2014Joseph TruittEVPSell25,000$7.82$195,500.00View SEC Filing  
6/16/2014Qvt Associates Gp LlcMajor ShareholderSell1,819,551$7.70$14,010,542.70View SEC Filing  
6/11/2014Qvt Associates Gp LlcMajor ShareholderSell128,649$7.66$985,451.34View SEC Filing  
6/10/2014Joseph TruittEVPSell50,000$6.02$301,000.00View SEC Filing  
6/10/2014Michael D KishbauchDirectorSell371,937$7.75$2,882,511.75View SEC Filing  
12/30/2013Qvt Associates Gp Llcmajor shareholderSell170,239$3.34$568,598.26View SEC Filing  
12/26/2013Qvt Associates Gp Llcmajor shareholderSell121,205$3.44$416,945.20View SEC Filing  
12/23/2013Qvt Associates Gp Llcmajor shareholderSell289,141$3.24$936,816.84View SEC Filing  
12/19/2013Qvt Associates Gp Llcmajor shareholderSell222,612$3.09$687,871.08View SEC Filing  
12/17/2013Qvt Associates Gp Llcmajor shareholderSell92,803$3.11$288,617.33View SEC Filing  
11/22/2013Dennis LiottaDirectorBuy10,000$2.98$29,800.00View SEC Filing  
11/20/2013Ra Capital Management, LlcInsiderBuy1,110,000$2.55$2,830,500.00View SEC Filing  
11/19/2013Jason FishermanDirectorBuy15,000$2.63$39,450.00View SEC Filing  
11/12/2013Ra Capital Management, LlcInsiderBuy1,795,000$2.48$4,451,600.00View SEC Filing  
10/31/2013Ra Capital Management, LlcInsiderBuy1,186,007$2.45$2,905,717.15View SEC Filing  
10/14/2013Ra Capital Management, LlcInsiderBuy2,369,229$2.79$6,610,148.91View SEC Filing  
10/11/2013Ra Capital Management, LlcInsiderBuy2,448,710$2.56$6,268,697.60View SEC Filing  
9/30/2013Ra Capital Management, LlcInsiderBuy2,800,000$2.98$8,344,000.00View SEC Filing  
8/14/2013Jason FishermanDirectorBuy5,000$6.83$34,150.00View SEC Filing  
8/12/2013Dennis LiottaDirectorBuy5,000$6.47$32,350.00View SEC Filing  
8/9/2013Qvt Associates Gp Llcmajor shareholderBuy102,282$6.41$655,627.62View SEC Filing  
7/11/2013Qvt Associates Gp LlcMajor ShareholderBuy401,017$6.46$2,590,569.82View SEC Filing  
7/10/2013Qvt Associates Gp LlcMajor ShareholderBuy390,944$6.33$2,474,675.52View SEC Filing  
7/8/2013Qvt Associates Gp LlcMajor ShareholderBuy642,509$6.28$4,034,956.52View SEC Filing  
7/3/2013Qvt Associates Gp LlcMajor ShareholderBuy1,963,248$6.43$12,623,684.64View SEC Filing  
7/1/2013Gary E FrashierDirectorSell5,000$8.17$40,850.00View SEC Filing  
6/21/2013Jason S FishermanDirectorBuy10,000$7.63$76,300.00View SEC Filing  
6/7/2013Gary E FrashierDirectorSell5,000$8.37$41,850.00View SEC Filing  
6/3/2013Jason S FishermanDirectorBuy10,000$7.87$78,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateHeadline logoAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Is Gearing Up For Interim HCV Release Next Month (NASDAQ:ACHN) - August 12 at 3:17 PM logoACHILLION PHARMACEUTICALS INC Financials (NASDAQ:ACHN) - August 12 at 3:17 PM logoIs Achillion Pharmaceuticals (ACHN) Stock a Solid Choice Right Now? (NASDAQ:ACHN) - August 12 at 11:51 AM logoAchillion Pharma (ACHN) Announces Presentation of Odalasvir, AL-335 and Simeprevir Phase 2b Data (NASDAQ:ACHN) - August 11 at 12:18 PM logoAchillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored Trial of Odalasvir, AL-335 and Simeprevir at the European Association for the Study of the Liver (EASL) Special Conference (NASDAQ:ACHN) - August 11 at 12:18 PM
News IconAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) To Feature A Presentation At The 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:ACHN) - August 10 at 12:01 PM logoETF’s with exposure to Achillion Pharmaceuticals, Inc. : August 9, 2016 (NASDAQ:ACHN) - August 9 at 3:25 PM logoAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : August 8, 2016 (NASDAQ:ACHN) - August 8 at 3:17 PM logoAchillion Pharmaceuticals Inc. (ACHN) Jumps 6.67% on August 05 - (NASDAQ:ACHN) - August 6 at 3:19 PM logoAchillion Pharmaceuticals Inc.: Achillion Reports Second Quarter 2016 Financial Results (NASDAQ:ACHN) - August 4 at 8:59 PM logoACHILLION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ACHN) - August 4 at 8:59 PM logoACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:ACHN) - August 4 at 8:59 PM logoAchillion Reports Second Quarter 2016 Financial Results (NASDAQ:ACHN) - August 4 at 8:59 PM logo4:36 pm Achillion Pharma beats by $0.01 (NASDAQ:ACHN) - August 4 at 8:59 PM logoQ2 2016 Achillion Pharmaceuticals Inc Earnings Release - Tentative - Before Market Open (NASDAQ:ACHN) - August 4 at 11:48 AM logoAnalysts Spotlight: UnitedHealth Group (NYSE:UNH) , Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Street Updates (NASDAQ:ACHN) - July 26 at 3:17 PM
News IconHot Biotech Stocks Recap: Achillion Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ACHN) - July 25 at 3:17 PM logoStocks Trend Analysis: Harsco Corporation (HSC) Hancock Holding Company (HBHC) Achillion Pharmaceuticals, Inc ... - iStreetWire (NASDAQ:ACHN) - July 23 at 9:00 AM
News Icon2 Biotech Stocks News And Price Trends: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Sarepta Therapeutics, Inc ... - The Voice Registrar (NASDAQ:ACHN) - July 22 at 11:27 AM
News IconAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:ACHN) - July 20 at 3:35 PM
News Icon2 Biotech Stocks News And Price Trends: PDL BioPharma (PDLI), Achillion Pharmaceuticals (NASDAQ:ACHN) - The Voice Registrar (NASDAQ:ACHN) - July 20 at 3:35 PM logoAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : July 20, 2016 (NASDAQ:ACHN) - July 20 at 8:10 AM
News IconNews review of 2 biotech stocks: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Celgene Corporation (NASDAQ ... - The Voice Registrar (NASDAQ:ACHN) - July 19 at 3:17 PM
News IconBiotech news that matter for investors: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN) - The Voice Registrar (NASDAQ:ACHN) - July 19 at 3:17 PM
News IconEarnings Estimates to see: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - News Oracle (NASDAQ:ACHN) - July 18 at 3:16 PM
News IconShare Performance Summary for: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph (NASDAQ:ACHN) - July 18 at 8:05 AM logoNext Weeks Broker Price Targets For Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Fiscal Standard (NASDAQ:ACHN) - July 17 at 8:03 AM logoAchillion Pharmaceuticals Inc. (ACHN) is Trading Lower on Unusual Volume for July 14 - (NASDAQ:ACHN) - July 17 at 8:03 AM logoAchillion Pharmaceuticals Inc Realized Volatility Hits Elevated Level - CML News (NASDAQ:ACHN) - July 15 at 1:53 PM logoAchillion Pharma Initiated At Sell By Chardan, Sees ≥60% Downside (NASDAQ:ACHN) - July 14 at 8:46 PM
News IconCrowd Rating and Earnings Recap for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Telanagana Press (NASDAQ:ACHN) - July 14 at 3:18 PM logoStrong Sell Calls For Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) At 1 - Investor Newswire (NASDAQ:ACHN) - July 14 at 12:08 PM logoCoverage initiated on Achillion Pharma by Chardan Capital Markets (NASDAQ:ACHN) - July 14 at 5:20 AM
News IconAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Earnings Rundown and Analyst Rating Recap - Telanagana Press (NASDAQ:ACHN) - July 13 at 8:50 PM logoTrade of the Day: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) (NASDAQ:ACHN) - July 11 at 9:04 AM
News IconCompany Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) Rally 13.82% - TheFounders Daily (NASDAQ:ACHN) - July 11 at 8:03 AM
News IconStock Performance Rundown on: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph (NASDAQ:ACHN) - July 11 at 8:03 AM
News IconAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Check on Company Stock Performance - Press Telegraph (NASDAQ:ACHN) - July 10 at 3:16 PM
News IconCompany Share Performance in Review: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph (NASDAQ:ACHN) - July 10 at 3:16 PM
News IconRa Capital Management LLC Increased Achillion Pharmaceuticals INC (NASDAQ:ACHN) by $5.67 Million as Shares ... - Press Telegraph (NASDAQ:ACHN) - July 9 at 11:24 AM
News IconNews Sentiment and Impact Score Review for :Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph (NASDAQ:ACHN) - July 8 at 3:18 PM logoAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : July 8, 2016 (NASDAQ:ACHN) - July 8 at 8:13 AM logoAchillion Pharmaceuticals, Inc. Stock Momentum Hits Strength - CML News (NASDAQ:ACHN) - July 7 at 8:36 PM
News IconEarnings Review and Price Target Watch for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph (NASDAQ:ACHN) - July 7 at 3:18 PM logoAchillion Pharmaceuticals (ACHN) Stock Up, JMP Upgrades (NASDAQ:ACHN) - July 7 at 10:44 AM logoAnalysts' Actions -- First Solar, Qualcomm, Red Hat, Zions and More (NASDAQ:ACHN) - July 7 at 8:10 AM
News IconWhich Way is Stock Sentiment Leaning on :Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph (NASDAQ:ACHN) - July 6 at 3:17 PM logoBroker Outlook For Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Fiscal Standard (NASDAQ:ACHN) - July 6 at 8:04 AM
News IconRecommendation View and Earnings Glance for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph (NASDAQ:ACHN) - July 5 at 3:17 PM
News IconAchillion Pharmaceuticals Inc (NASDAQ:ACHN): Stock Sentiment - Engelwood Daily (NASDAQ:ACHN) - July 5 at 8:04 AM


Achillion Pharmaceuticals (NASDAQ:ACHN) Chart for Tuesday, August, 23, 2016

Last Updated on 8/23/2016 by Staff